Rchr
J-GLOBAL ID：201901008481907434
Update date: Sep. 30, 2022
Hirata Masahiko
ヒラタマサヒコ | Hirata Masahiko
Affiliation and department：
Osaka University of Pharmaceutical Sciences
About Osaka University of Pharmaceutical Sciences
Search "Osaka University of Pharmaceutical Sciences"
Research keywords (5)：
がん
, 中性子補足療法
, PET
, SPECT
, Radiophamacrutical
Research theme for competitive and other funds (4)：
2017 - 2020 ポストFDGを目指した新規放射性薬剤の開発~p38α活性診断薬剤の開発~
2011 - 2014 EGFシグナル阻害による癌治療計画の支援システム構築を目指した新規診断薬の開発
2007 - 2010 癌の早期診断と抗癌剤の薬効予測可能な新規シグナル伝達分子イメージング薬剤の開発
2000 - 2001 癌ならびに痴呆の超早期診断を目指したMAPキナーゼ活性診断用新規放射性薬剤の開発
Papers (15)：
Masahiko Hirata. Synthesis and characterization of novel radiofluorinated probes for positron emission tomography imaging of monoamine oxidase B. J Labelled Comp Radiopharm. 2019. 62. 9. 590-587
Masahiko Hirata. Development of a p38α-selective radioactive probe for qualitative diagnosis of cancer using SPECT. Ann Nucl Med. 2019. 33. 5. 333-343
Masahiko Hirata. PET probe detecting non-small cell lung cancer susceptible to epidermal growth factor receptor tyrosine kinase inhibitor therapy. Bioorg Med Chem. 2018. 26. 8. 1609-1613
Masahiko Hirata. Development of novel PET probes targeting phosphatidylinositol 3-kinase (PI3K) in tumors. Nucl Med Biol. 2016. 43. 1. 101-107
Mamiko Asano, Mitsunobu Doi, Kimiye Baba, Masahiko Taniguchi, Makio Shibano, Satoshi Tanaka, Minoru Sakaguchi, Masanori Takaoka, Masahiko Hirata, Rika Yanagihara, et al. Bio-imaging of hydroxyl radicals in plant cells using the fluorescent molecular probe rhodamine B hydrazide, without any pretreatment. JOURNAL OF BIOSCIENCE AND BIOENGINEERING. 2014. 118. 1. 98-100
ｍore...
Patents (1)：
4-フェノキシキナゾリン誘導体放射性化合物
Education (1)：
- 1994 京都大学大学院 薬学研究科 博士課程
Association Membership(s) (4)：
日本中性子補足療法学会
, 日本分子イメージング学会
, JAPANESE SOCIETY OF NUCLEAR MEDICINE
, THE PHARMACEUTICAL SOCIETY OF JAPAN
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM
